Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura
NCT02553317Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2015
- Primary completion
- Aug 2017
- Modality
- Nanobodies (VHH)
- Countries
- 16
01
Overview
A Phase 3 trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Sanofi. Started Nov 2015; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT02553317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553317.